Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/06 03:43:10 am
8256.5 GBX   +0.80%
03:33aLONDON STOCK EXCHANGE : FTSE 100 gains after choppy week with oil stocks in lead
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
01:21aPfizer accused of funding anti- AstraZeneca info
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaccinated but stuck: Indians await WHO nod for homegrown shot to travel abroad

10/26/2021 | 02:58am EST

PANDALAM, India, Oct 26 (Reuters) - Stuck in a village in southern India for nine months and unable to return to his job in Saudi Arabia, Sugathan P.R. is hoping the World Health Organization will approve the Indian COVID-19 shot Covaxin, paving the way for his trip back.

Like Sugathan, millions of Indians have taken Covaxin and many have complained of travel struggles as the vaccine has not been recognised for international travel by several countries.

"I cannot continue to remain idle here any further," said 57-year-old Sugathan, who returned to Pandalam village in Kerala in January to be with his family after missing his father's funeral last year when the pandemic disrupted flights.

"I had the option of going to Saudi and taking (additional doses of) Covishield after a four-day institutional quarantine, but I was not sure of its implications on my health," said Sugathan, referring to AstraZeneca's vaccine.

"If the Covaxin approval does not come, I will take the risk of going and taking a Saudi-approved vaccine," he added, sitting in his spacious two-storey house fronted by paddy fields.

The WHO is expected to take a final call on an emergency-use listing for Covaxin on Tuesday.

It has deliberated on data supplied by manufacturer Bharat Biotech since early July but has said it could not "cut corners https://www.reuters.com/business/healthcare-pharmaceuticals/who-expects-more-information-indias-bharat-biotech-its-covid-19-vaccine-2021-10-18 " in making a decision.

Without a WHO nod, the two-dose Covaxin is unlikely to be accepted as a valid vaccine globally and would complicate travel plans for Indians who have taken it.

Rajan Pallivadakethil Unnunni, 59, who worked in Kuwait as a welder for two decades before flying to India late last year, has been unable to go back as Kuwait does not recognise Covaxin.

He is now struggling to repay his $20,000 bank loan selling chicken at a small stall in Kerala and making $4 a day.

"If I cannot go back to Kuwait, I will not be able to repay the loan and complete the education of my children," said Rajan, seated on a plastic stool in front of his shop.

"I can buy a ticket to Kuwait only if the Kuwait government app shows a green signal." (Writing by Krishna N. Das; Editing by Himani Sarkar)

ę Reuters 2021
All news about ASTRAZENECA PLC
03:33aLONDON STOCK EXCHANGE : FTSE 100 gains after choppy week with oil stocks in lead
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
01:21aPfizer accused of funding anti- AstraZeneca info
01:00aCOVID shots are finally arriving, but Africa can't get them all into arms
12/05Pfizer Denies Claims of Funding Misinformation Against AstraZeneca's COVID-19 Jab
12/04Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection
12/03AstraZeneca Explores Listing of Newly-Created Vaccines Unit
12/03AstraZeneca Reportedly Weighs Listing of Newly-Created Vaccines Unit
12/03European Stocks Close Lower After Disappointing US Jobs Data
12/03AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Undersco..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 36,9x
Yield 2021 2,60%
Capitalization 168 B 168 B -
EV / Sales 2021 5,38x
EV / Sales 2022 4,40x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 108,38 $
Average target price 137,48 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.84%167 779
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010